The Zelda Therapeutics Ltd share price is down 7%

The Zelda Therapeutics Ltd (ASX: ZLD) share price has been one of the worst performing shares on the market today.

In afternoon trade the medicinal cannabis company’s shares are down almost 7% to 7 cents.

Why has it fallen?

Today’s decline appears to be a case of profit taking. After all, Zelda’s shares rallied strongly towards the start of June after it announced a strategic manufacturing and distribution agreement with Chile-based Knop Laboratorios.

As well as locking in a high quality supply of Zelda’s formulated medicinal-cannabis medicines for its upcoming clinical trials, investors appeared to be pleased that the agreement secured a scalable and GMP-grade source of commercial quantities following product registration.

Zelda’s trials are focused on insomnia, eczema and autism. Results for its insomnia and eczema trials are expected to be released by the end of the year.

Here’s a recent review of listed shares in the growing pot stock industry.

OUR #1 dividend pick to grow your wealth over the new financial year is revealed for FREE here!

Financial year 2018 is here and The Motley Fool's dividend detective Andrew Page has revealed his must buy dividend share to grow your wealth in 2018.

You probably don't know this market leader, but it's making waves in Asia and already boasts a term-deposit-crushing dividend above 4%. A debt free balance sheet and dominant market position at home and abroad mean this company offers investors income and some real-deal growth potential...

Simply click here to grab your FREE copy of this up-to-the-minute research report on this rising star right now.

Motley Fool contributor Motley Fool Staff has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.